Minimal residual disease (MRD) detected by quantitation of NPM1-mutated transcripts is more predictive of relapse and survival than molecular profiling in patients with NPM1-mutated acute myeloid leukemia (AML), according to a study of 2,569 samples obtained from 346 patients with NPM1-mutated AML. Persistence of NPM1-mutated transcripts in blood was present in 15% of patients after a second chemotherapy cycle and was significantly associated with a greater risk of 3-year relapse than was an absence of such transcripts (82% vs. 30%; p<0.001) and a lower rate of survival (24% vs. 75%; p<0.001). MRD was the only independent prognostic factor for death in a multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; p<0.001). The researchers concluded that determining MRD by quantitation of NPM1-mutated transcripts provides “powerful prognostic information independent of other risk factors.”
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Minimal Residual Disease a Powerful Prognosticator in Standard-Risk AML
Feb 2016